Hikma Ventures leads Series B expansion of Activ Surgical to support global commercialization of its platform

LONDON and BOSTON, March 22, 2022 /PRNewswire/ — Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announced that its venture capital subsidiary, Hikma Ventures led a 15 million US dollars round of funding for active surgery, a pioneering digital surgical imaging startup that develops breakthrough interoperative surgical intelligence hardware and software. The investment is an extension of the Series B round which was previously announced by Activ Surgical in September 2021. This most recent funding, which also saw participation from existing investors, brings the total Series B round to US$60 million.

Activ Surgical aims to revolutionize access to surgical care, enabling a future of augmented reality (AR) and artificial intelligence (AI)-based surgery that is safe, smart and accessible to everyone. The Company’s Patented Surgical Intelligence Platform – ActivEdge™ – is designed to reduce unintended and preventable surgical errors by improving a surgeon’s interoperative decision-making through the use of AI. Activ Surgical’s first product, the ActivSight™ Imaging Module, seamlessly upgrades existing operating room equipment, serving as the “eyes” of the ActivEdge platform. It allows surgeons to access critical intraoperative visual data in the form of AR overlays. In 2021, the ActivSight imaging module was FDA cleared and successfully used in its first human studies. To date, several large hospital networks in the United States and Europe were established as pilot sites. The ActivSight Imaging Module is available now through a limited release and will be widely available in 2022.

“Hikma Ventures’ investment in Activ Surgical comes at a critical inflection point in the company’s history, as our team works hard to prepare for the global launch of our ActivSight imaging module later this year” , said Todd Usen, CEO, Activ Surgical. “This investment will allow us to rapidly scale our business and add the resources needed to ensure a successful deployment of the ActivSight Imaging Module, helping to fulfill our mission to empower surgeons’ intraoperative decision-making and ultimately account, to improve patient safety. Hikma’s position in the global healthcare landscape helps validate our mission to deliver better patient outcomes globally. »

“We are thrilled to invest in Activ Surgical and support their mission to democratize surgical care and eliminate unintended surgical complications to improve patient outcomes and empower surgeons around the world,” said Lana Ghanem, Managing Director of Hikma Ventures. “This is the latest example of Hikma Ventures’ commitment to supporting pioneering companies using cutting-edge technologies to meaningfully improve the lives of patients. We look forward to working with the talented team at Activ Surgical to help them to expand the global reach of their innovative platform for different geographies, in particular the Middle East.”

Investor requests:

Hikma Ventures

Lana Ghanem

[email protected]

Managing Director, Hikma Ventures

+962 6 580 3100


Steve Weiss

+1 732 788 8279

David Belian

+1 848 254 4875

Communications and Public Affairs in the United States

[email protected]

US Media Contact for Activ Surgical:

Heat Meyer ([email protected] / 858-768-1527)

About Hikma
(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB-/stable S&P and BBB-/stable Fitch)
Hikma helps put better health within reach every day for millions of people around the world. For more than 40 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. Based in the UK, we are a global company with a local presence across United States (We the Middle East and North Africa (MENA) and Europe, and we use our unique knowledge and expertise to turn cutting-edge science into innovative solutions that transform people’s lives. We are committed to our customers and the people they care for, and by thinking creatively and acting practically, we provide them with a wide range of branded and unbranded generic medicines. Together, our 8,600 colleagues help shape a healthier world that enriches all of our communities. We are a premier licensing partner, and through our venture capital arm, we help bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

About Hikma Ventures
Founded in August 2015, Hikma Ventures operates as the corporate venture capital arm of Hikma Pharmaceuticals. Hikma Ventures invests in global start-ups where Hikma’s expertise can accelerate revenue growth and enhance value creation by providing companies with access to the resources of a multinational pharmaceutical company. For more information, please visit www.hikmaventures.com.

About Activ Surgical
active surgery is the pioneering digital surgery company that performed the world’s first autonomous robotic soft tissue surgery in 2018. The company is revolutionizing surgical vision, enabling a future of augmented reality and artificial intelligence-based surgery that is safe, intelligent and accessible to all. Its patented surgical software platform–ActivEdge™— is designed to reduce unintended and preventable surgical errors by improving a surgeon’s intraoperative decision-making through the aggregation of surgical data from around the world. Activ Surgical is privately held and supported by Hikma Ventures, DNS Capital, Capital Cota, BAM funds, GreatPoint Ventures (GPV), ARTIS Ventures, LRVHealth, Tao Capital Partners, Capital of Magnetar, Nvidia, Rising tide VC, MINT Venture Capital Partners, Beaver Companies, SONY Innovation Fundand dream a vision. Learn more about www.activsurgical.com.

SOURCE Hikma Pharmaceuticals United States Inc.

Christine E. Phillips